Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LENZ Therapeutics

交易中 11-09 14:34:02 EST

4.23

+0.73

+20.86%

最高4.28	最低3.40	成交量96.98万
今开3.57	昨收3.50	日振幅25.14%
总市值1.32亿	流通市值8,655万	总股本3,129万
成交额386.32万	换手率4.74%	流通股本2,046万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.23,"timestamp":1794252839974,"preClose":3.5,"halted":0,"volume":969809,"delay":0,"changeRate":0.20857142857142869,"floatShares":20461200,"shares":31289969,"eps":-4.482297,"marketStatus":"交易中","change":0.73,"latestTime":"11-09 14:34:02 EST","open":3.57,"high":4.28,"low":3.4,"amount":3863192.3527321,"amplitude":0.251429,"askPrice":4.24,"askSize":30,"bidPrice":4.22,"bidSize":209,"shortable":3,"etf":0,"ttmEps":-4.482297,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794258000000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.55,"preClose":3.5,"latestTime":"09:13 EST","volume":2534,"amount":9019.2365522,"timestamp":1794233635387,"change":0.05,"changeRate":0.014286,"amplitude":0.077143},"postHourTrading":{"tag":"盘后","latestPrice":3.51,"preClose":3.5,"latestTime":"19:30 EST","volume":3913,"amount":13674.8743,"timestamp":1794011402640,"change":0.01,"changeRate":0.002857,"amplitude":0.002857},"volumeRatio":0.941998,"impliedVol":0.925,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2681027219","title":"荃信生物-B与Caldera Therapeutics签署独家授权协议 最高可获7.5亿美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027219","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681027219?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:25","pubTimestamp":1793881500,"startTime":"0","endTime":"0","summary":"11月5日，荃信生物-B（02509）发布公告，公司于今日与CalderaTherapeutics就一项靶向TL1A及IL-17的临床前阶段双特异性抗体项目订立独家授权协议。根据协议，CalderaTherapeutics获授独家、须支付特许权使用费、可转让及可再授权的权利，以在全球范围内研究、开发、注册、生产及商业化源自许可项目的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611053923714637.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611053923714637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","02509","LENZ","BK4007","BK1161","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680709130","title":"基石药业-B(02616)与Kimia Therapeutics达成临床开发合作，共同推进一款靶向实体瘤关键修复通路的创新候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2680709130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680709130?lang=zh_cn&edition=full","pubTime":"2026-11-04 08:06","pubTimestamp":1793750760,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司已与专注于肿瘤及免疫创新药物研发的生物制药公司Kimia Therapeutics, Inc.达成合作。双方将共同推进一款具备同类首创潜力，靶向实体瘤生存关键DNA损伤应答通路的实体瘤候选药物的临床开发。基石药业将主导该候选药物在中国大陆及澳大利亚的临床开发工作。此次合作进一步印证了业界对基石药业成熟临床开发及药品注册能力的国际认可，也契合公司审慎推进外部创新与全球化布局的战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4539","BK1161","02616","BK4139","LENZ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679688246","title":"美股异动 | Bambusa Therapeutics(BBTX.US)登陆美股市场 股价跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679688246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679688246?lang=zh_cn&edition=full","pubTime":"2026-10-31 00:03","pubTimestamp":1793376223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Bambusa Therapeutics登陆美股市场，截至发稿，该股跌超8%，报14.685美元。IPO价格为16美元。Bambusa Therapeutics是一家总部位于美国波士顿的临床阶段生物制药公司，专注于开发治疗免疫系统及炎症性疾病的新一代长效双特异性抗体药物。公司的主要在研药物BBT001用于治疗特应性皮炎(湿疹)、慢性自发性荨麻疹等皮肤疾病；另一款候选药物BBT002则主要针对哮喘、慢性阻塞性肺病及慢性鼻窦炎伴鼻息肉等炎症性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","LENZ","BBTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679324668","title":"美股异动 | Bambusa Therapeutics(BBTX.US)登陆美股市场 股价跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679324668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679324668?lang=zh_cn&edition=full","pubTime":"2026-10-31 00:03","pubTimestamp":1793376223,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677979350","title":"美股异动 | 生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场 股价涨超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677979350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677979350?lang=zh_cn&edition=full","pubTime":"2026-10-24 00:27","pubTimestamp":1792772851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，专注于过敏和自身免疫性疾病治疗的生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场，开盘后股价涨超32%，报23.9美元。IPO价格为18美元。Lycia Therapeutics致力于开发旨在降解致病细胞外蛋白的疗法，初期聚焦自身免疫、炎症和过敏性疾病。其技术平台名为LYTAC(溶酶体靶向嵌合体)，基于诺贝尔奖得主Carolyn Bertozzi在斯坦福大学的研究工作。其主要候选药物LCA-0061旨在降解免疫球蛋白E(IgE)，用于治疗包括食物过敏在内的过敏性疾病，目前处于一期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","MEDX","LENZ","IEIH","BK4588","LYCA","XBI","AGNG","BK4581","BK4139","BK4539","GDOC","BK4585","HBImain","SYNB","IBBJ","BK4007","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677496908","title":"Vera Therapeutics宣布ORIGIN 3最终疗效结果积极。","url":"https://stock-news.laohu8.com/highlight/detail?id=2677496908","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677496908?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:07","pubTimestamp":1792678040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4588","LU2324357040.USD","VERA","LENZ","BK4539","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677280556","title":"过敏及自免生物技术公司Lycia Therapeutics(LYCA.US)IPO定价16-18美元/股 拟募资2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677280556","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677280556?lang=zh_cn&edition=full","pubTime":"2026-10-21 14:57","pubTimestamp":1792565853,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物技术公司Lycia Therapeutics周二公布首次公开募股条款。按拟议发行价区间中点计算，Lycia Therapeutics的完全稀释市值将达到约9.5亿美元。Lycia Therapeutics致力于开发旨在降解致病细胞外蛋白的疗法，初期聚焦自身免疫、炎症和过敏性疾病。此外，公司正在开展LCA-0321的一期临床试验，该药物旨在选择性降解引发格雷夫斯病的自身抗体。Lycia Therapeutics成立于2019年，截至2026年6月30日的12个月内实现营收400万美元。预计10月19日当周定价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LYCA","UDN","WDNA","BK4139","BK4539","UUP","HELX","LENZ","BK4007","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676630607","title":"德国默克斥13亿美元收购Silence Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2676630607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676630607?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:13","pubTimestamp":1792458828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676516184","title":"美股异动 | 生物技术公司City Therapeutics(CTY.US)登陆美股市场 开盘后涨近24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676516184","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676516184?lang=zh_cn&edition=full","pubTime":"2026-10-17 00:00","pubTimestamp":1792166400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，City Therapeutics登陆美股市场，截至发稿，该股涨近24%，报22.315美元。City Therapeutics是一家总部位于美国马萨诸塞州剑桥市的临床阶段生物技术公司，成立于2023年，专注于开发新一代RNA干扰疗法，通过抑制与疾病相关的特定蛋白质表达，治疗具有重大未满足医疗需求的疾病。公司由RNAi领域资深专家创立，联合创始人兼执行董事长John Maraganore曾担任RNAi制药先驱Alnylam的首席执行官。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CTY","WDNA","BK4139","BK4539","HELX","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356164","title":"杰富瑞将Spyre Therapeutics列为2027年生物科技首选股，三款炎症性肠病联合疗法将公布临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356164","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675356164?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:26","pubTimestamp":1792135560,"startTime":"0","endTime":"0","summary":"10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。Spyre目前正在推进三款针对溃疡性结肠炎和克罗恩病的联合治疗方案，预计均将在2027年公布II期临床试验数据。杰富瑞认为，这些结果表明，通过联合不同炎症通路的治疗机制，可能进一步改善炎症性肠病患者的临床疗效。截至10月15日收盘，Spyre股价上涨1.87%，报80.10美元。对于未来一年，杰富瑞最关注的仍是三款炎症性肠病联合疗法的II期临床结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-16/doc-inivmazi7741271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","IBBJ","BK4581","GDOC","XBI","SYNB","BK4559","159837","BK4539","AGNG","BK4127","IEIH","HBImain","MEDX","BK4588","BK4585","LNGR","BK4007","JEF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674850360","title":"City Therapeutics冲刺美股：拟募资1.8亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2674850360","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674850360?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:14","pubTimestamp":1791555254,"startTime":"0","endTime":"0","summary":"RNAi药物开发商City Therapeutics Inc(股票代码：“CTY”）日前更新招股书，准备2026年10月16日在美国纳斯达克上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261009/6392718082355915708199015.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261009/6392718082355915708199015.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35357/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4007","BK4539","LENZ","BK4139","PPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851717","title":"富达、Arch站台，RNAi新锐City Therapeutics(CTY.US)冲刺美股IPO，拟募资至多1.85亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674851717?lang=zh_cn&edition=full","pubTime":"2026-10-09 20:23","pubTimestamp":1791548622,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CTY","BK4139","FRHC","BK4007","LENZ","KCE","BK4539","IPOS","BK4127","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830635","title":"Definium Therapeutics股价盘前上涨4%，此前摩根大通首次覆盖该股并给予增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830635?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:31","pubTimestamp":1791538312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","PGF","DFTX","BK4139","BK4007","BK4582","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674836788","title":"小分子生物技术公司Iambic Therapeutics(IAM.US)IPO定价15-17美元/股 拟筹资1.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674836788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674836788?lang=zh_cn&edition=full","pubTime":"2026-10-09 14:50","pubTimestamp":1791528639,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，依托自研人工智能平台开发小分子抗癌疗法、处于一期临床阶段的生物技术公司Iambic Therapeutics于周四公布了其IPO条款。按拟发行价区间中值计算，Iambic Therapeutics的完全摊薄市值将达到8.09亿美元。据了解，Iambic Therapeutics是一家临床阶段的生物技术公司，将专有AI模型与自动化高通量化学和生物学相结合，用于设计小分子药物。Iambic Therapeutics成立于2019年，截至2026年6月30日的过去12个月实现营收1800万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UUP","BK4539","HELX","LENZ","BK4007","WDNA","BK4139","UDN","IPOS","IAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672786793","title":"United Therapeutics股价上涨12.2%，此前该公司赢得了针对Liquidia的法院裁决。","url":"https://stock-news.laohu8.com/highlight/detail?id=2672786793","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672786793?lang=zh_cn&edition=full","pubTime":"2026-10-01 00:32","pubTimestamp":1790785955,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671878563","title":"United Therapeutics股价上涨11%，创下自3月份以来的最大涨幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671878563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671878563?lang=zh_cn&edition=full","pubTime":"2026-09-30 23:28","pubTimestamp":1790782109,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671221063","title":"美股异动｜Summit Therapeutics大涨超23%，获阿斯利康20亿美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=2671221063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671221063?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:58","pubTimestamp":1790690324,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217716","title":"美股开盘，uniQure 跌 39%，Summit Therapeutics 涨 19.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217716","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671217716?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688703,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据 Gate 行情数据显示，美股开盘，道指跌 0.1%，标普 500 指数涨 0.13%，纳指涨 0.3%。生物制药公司 uniQure 跌 39%，因其亨廷顿症基因疗法的 48 个月数据未达统计显著性。Summit Therapeutics 涨 19.2%，此前阿斯利康拟向该公司投资 20 亿美元合作开发抗癌药物。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2293025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162346253","title":"美股开盘｜标普小幅高开；Summit Therapeutics涨逾20%、纳微半导体涨超12%；芯片股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1162346253","media":"美股开盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162346253?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688673,"startTime":"0","endTime":"0","summary":"热门个股方面，Summit Therapeutics涨20.16%，因获阿斯利康20亿美元投资；纳微半导体涨7.50%，获得美国陆军拨款开发碳化硅器件；三倍做多半导体ETF-Direxion Daily涨4.30%；迈威尔科技涨2.72%，受AI数据中心需求提振；英伟达涨0.88%，1500亿美元回购计划强化信心；另一方面，Fair Isaac跌19.79%，因竞争加剧打压盈利预期。Summit Therapeutics获阿斯利康20亿美元投资。双方将联合开发创新癌症疗法，巨额资金与合作前景带动Summit股价大涨逾20%。AT&T与康宁签署逾30亿美元光纤供应协议。Fair Isaac遭下调评级股价重挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BERZ","BK4007","XSEM","BK4539","ESmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671929450","title":"Summit Therapeutics美股盘前涨超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671929450","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671929450?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:01","pubTimestamp":1790668879,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.1475},{"period":"1month","weight":-0.0331},{"period":"3month","weight":-0.347},{"period":"6month","weight":-0.6521},{"period":"1year","weight":-0.8476},{"period":"ytd","weight":-0.7813}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"LENZ Therapeutics, Inc.最初于2017年6月1日在加拿大安大略省注册成立，随后于2019年10月在特拉华州重新注册成立。该公司是一家商业制药公司，专注于开发和商业化改善视力的疗法，其主导产品VIZZ被批准用于治疗老花眼。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.5,"avgChangeRate":-0.02143},{"month":10,"riseRate":0.5,"avgChangeRate":-0.090577},{"month":11,"riseRate":0.666667,"avgChangeRate":0.020047},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Therapeutics(LENZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}